Emerging biologics called T cell engagers are poised to transform autoimmune disease treatment by enabling an 'immune reset.' Unlike conventional broad immunosuppression, these agents directly link T cells to autoreactive B and plasma cells to eliminate disease-driving immune components. This therapeutic strategy aims for durable remission rather than symptom control. Researchers highlight T cell engagers as a scalable alternative to CAR T therapies, with simpler administration methods potentially enhancing patient experience and outcomes.